Affidea Appoints Dr Rowland Illing as Chief Medical Officer

2015.09.28

 

As of September 28th, Affidea is delighted to welcome its new Chief Medical Officer, Dr Rowland Illing. Dr Illing is a highly qualified radiologist with an extensive list of significant academic qualifications, all of which focus on radiology and diagnostic imaging. “Rowland is ideally placed to lead the company in medical matters and improve quality and safety even further throughout our organisation. We are very pleased to have him on board,” said Dimitris Moulavasilis, CEO Affidea.

Dr Illing also commented on joining Affidea: “My own ethos is reflected in the Affidea manifesto – nothing is more important than health. Affidea is led by an outstanding Executive Board and Board of Directors, has a strong and stable financial backing from Waypoint Capital and an exceptional Medical Advisory Board and Medical Council. As CMO I will have the opportunity to work with the team to influence and improve patient care on a truly global scale.”

Career Profile

Dr Illing graduated from Cambridge University and studied postgraduate medicine at Oxford University before training in Surgery at the Imperial College Hospitals and gaining membership of the Royal College of Surgeons in 2001.

He undertook a higher research degree in Oxford University into image-guided cancer therapy, using high-intensity focused ultrasound to destroy liver and kidney tumours. After a further year of research into image-guided prostate therapy at UCL he went on to formally train in imaging, becoming a fellow of the Royal College of Radiologists in 2009. 

He holds numerous research grants and sits on the trial steering groups of several nationally funded multicentre trials. He has published widely in peer-reviewed journals and presented his work in the international arena.